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This study compared Major Adverse Cardiac Event in patient with Acute 
Coronary Syndromes undergoing PCI with Drug Eluting Stents Vs Bare 
Metal Stents. A retrospective, observational study was carried out in an 
inpatient setting of the private tertiary care hospital. Patients with >18 years, 
diagnosed for Acute Coronary Syndromes (ACS), required intervention in 
coronary artery with implantation of Drug Eluting Stents (DES) or Bare 
Metal Stents (BMS) were recruited in the study. The data had been collected 
from file or database of the hospital. All subjects were followed for major 
adverse cardiac event. Result.  A total of 202 patients who underwent 
percutaneous coronary intervention (PCI) were enrolled into DES group 
(N=101) and BMS group (N=101).  All patients were followed up at 1 
month, 3 months, 6 months & 12 months for Major Adverse Cardiac Events 
(MACE). Clinical outcomes during 12 months were compared between DES 
group & BMS group. There was no significant difference in baseline 
parameters including demographic, risk factors of ACS, diagnosis, 
angiographic parameters between both groups. Overall MACE rates were 
reported non-significantly high in BMS group patients (14.85%) compare to 
DES group patients (8.91%) (P=0.458). However, DES group had lower 
rates of death (0.99% vs 1.98%, P=0.57), rate of MI (3.96% vs 4.95% 
P=0.73), rate of revascularization (1.98% vs 3.96% p=0.42) & rate of sub 
acute thrombosis (1.98% vs 3.96% P=0.42) and higher rate of bleeding 
(1.98% vs 0.99% p=0.57) compare to cohort-II. Conclusion. The use of DES 
in the setting of Acute Coronary Syndrome is associated with lower Major 
Adverse Cardiac Event (MACE) rate compared to BMS without 
compromising the overall safety over the course of one-year follow-up. The 
long-term safety of drug-eluting stents needs to be ascertained in large, 
randomized trials. 
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1. INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death and disability in the world. [1] Among 
these, coronary artery disease (CAD) is the most prevalent manifestation and is associated with high 
mortality and morbidity. India has the highest burden of acute coronary syndromes in the world, yet little is 
known about the treatments and outcomes of these diseases. There will be required to document the 
characteristics, treatments, and outcomes of patients with acute coronary syndromes who were admitted to 
hospitals in India. [2] 
Prospective, randomized clinical trials have shown that in-stent restenosis is reduced by the use of 
drug-eluting stents, as compared with bare-metal stents. However, the use of drug-eluting stents has rapidly 
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been expanded to all types of patients, including those with more complicated coronary lesions and in acute 
settings. Recently metaanalyses of randomized trials [3-4] and registries [5] have raised concern about 
incomplete neointimal coverage with a subsequent increase in late stent thromboses in patients with drug-
eluting stents. [6-7] One randomized trial indicated that the implantation of drug-eluting stents was associated 
with an early reduction in death and myocardial infarction — an improvement that was lost during the 
subsequent 6 to 18 months by a late increase in the same events. [8] We determined that the evaluation of 
large clinical registries might provide useful information concerning the long-term efficacy and safety of 
drug-eluting stents. Therefore, we evaluated the long-term outcome in all patients who underwent stent 
implantation.                 
 
 
2. RESEARCH METHOD 
A retrospective, open label, observational study carried out in an inpatient setting of the private 
tertiary care hospital. Patients with >18 years, diagnosed for Acute Coronary Syndromes (ACS), required 
intervention in coronary artery with implantation of Drug Eluting Stents (DES) or Bare Metal Stents (BMS) 
were recruited in the study. The data had been collected from file or database of the hospital. All subjects 
were followed for major adverse cardiac event (MACE) including death, Myocardial infarction, Urgent 
revascularization, sub acute thrombosis & bleeding at 1 month, 3 months, 6 months & 12 months after PCI. 
All collected data was analyzed in its group for clinical outcomes. All variables were analyzed using 
percentage, mean & standard deviation. Statistical difference between both cohorts was calculated by 
applying independent t-test & odds ratio. 
 
 
3. RESULTS & ANALYSIS 
There were 202 patients who underwent PCI between December 2008 and July 2009 was enrolled in 
retrospective, observational study. All these subjects were divided in two Cohorts. 
Cohort-1: Patients implanted Drug Eluting Stent (DES) (N=101) 
Cohort-2: Patients implanted Bare Metal stent (BMS) (N=101) 
 
 
Table 1. Demographic parameters 
Parameters Cohort-I Cohort-II P-value 
Age 56.34 ± 10.93 55.46 ± 12.47 0.59 
Gender-Male 87.13% (88) 89.11% (90) 0.66 
Weight 68.02 ± 11.33 69.8 ± 0.29 0.29 
Height 164.2 ± 9.55 164 ± 7.08 0.88 
BMI 25.25 ± 3.81 28.87 ± 3.74 0.24 
BSA 1.74 ± 0.17 1.76 ±0.17 0.48 
 
 
 
Figure 1. Age wise distribution of patients 
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Out of the 202 patients, 87.13% (N=88) and 89.11% (N=90) were male patients in Cohort-1 & 
Cohort-2 respectively. The average age of the patients were 56.34 & 55.46 in Cohort-1 & Cohort-2 
respectively (Table 1). Risk of acute coronary syndrome was increase with increasing age (Figure 1). 
Average BMI in cohort 1 & cohort 2 were 25.25 Kg/m2 & 28.87 Kg/m2 respectively. There was no 
significant difference in baseline demographic parameters between both groups (Table 1). 
There were no significant difference in hypertension (46.53% Vs 33.66% P=0.74), diabetes 
Mellitus-II (30.69% Vs 21.78% P=0.15), family history of CAD (22.77% Vs 24.75% P=0.06), prior history 
of CAD (15.84% Vs 11.88% P=0.42), smoker (14.85% Vs 22.77% P=0.15), tobacco chewer (15.84% Vs 
8.91% P=0.15), hyperlipidemia (1.98% Vs 1.98% P=1.00) in cohort-I & cohort-II respectively (Table 2).  
 
 
Table 2. Risk factors of Acute Coronary Syndromes 
Parameters Cohort-I Cohort-II P Value 
HTN 46.53% (47) 33.66% (34) 0.74 
DM-2 30.69% (31) 21.78% (22) 0.15 
Family History 22.77% (23) 24.75% (25) 0.06 
Smoker 14.85% (15) 22.77% (23) 0.15 
Prior H/O CAD 15.84% (16) 11.88% (12) 0.42 
Tobacco chewer 15.84% (16) 8.91% (9) 0.15 
Hyperlipidemia 1.98% (2) 1.98% (2) 1.00 
 
 
There were high number of subjects were reported as STEMI in both groups. STEMI was reported 
35.64% (36) Vs 34.66% (35), p=0.88 in Cohort-1 & Cohort-2 respectively. NSTEMI was reported 27.73% 
(28) Vs 31.68% (32), p=0.54 in Cohort-1 & Cohort-2 respectively. Unstable angina was reported 29.7% (30) 
Vs 30.69% (31), p=0.88 in Cohort-1 & Cohort-2 respectively. Stable angina was reported 6.93% (7) Vs 
2.97% (3), p=0.21 in Cohort-1 & Cohort-2 respectively (Figure 2).  
 
 
Figure 2. Diagnosis of Patients 
 
 
During coronary angiography (CAG), It was found that the main culprit vessel in coronary artery 
disease was LAD (66.34% & 54.45% in Cohort-1 & Cohort-2 respectively) followed by RCA (21.78% & 
23.76% in Cohort-1 & Cohort-2 respectively). There were high numbers of subjects having coronary stenosis 
>90% in both cohorts (49.5% & 52.47% in Cohort-1 & Cohort-2 respectively). Detail coronary angiographic 
findings were shown in Table 3. 
Overall MACE rates were reported non-significantly high in Cohort-I (8.91%) compare to Cohort-II 
(14.85%) (P = 0.458). However, Cohort-I had lower rates of death (0.99% vs 1.98%, P=0.57), rate of MI 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
STEMI NSTEMI Unstable angina Stable angina
Cohort-I Cohort-II
                ISSN: 2252-8806 
IJPHS  Vol. 1, No. 2,  December 2012 :  55 – 60 
58
(3.96% vs 4.95% P=0.73), rate of revascularization (1.98% vs 3.96% p=0.42) & rate of sub acute thrombosis 
(1.98% vs 3.96% P=0.42) and higher rate of bleeding (1.98% vs 0.99% p=0.57) compare to cohort II  
(Figure 3). 
 
 
Table 3. Angiographic findings 
Parameters Cohort-I Cohort-II P Value 
Type of Vessel       
LAD 66.34% (67) 54.45% (55) 0.09 
RCA 21.78% (22) 23.76% (24) 0.74 
LAD & RCA 4.95% (5) 3.96% (4) 0.73 
 LCX 3.96% (4) 10.89% (11) 0.07 
RAMUS 1.98% (2) 0% (0) 0.29 
SVG Graft 0.99% (1) 0% (0) 0.50 
OM-2 0% (0) 3.96% (4) 0.14 
LCX &LAD 0% (0) 0.99% (1) 0.50 
LMCA 0% (0) 0.99% (1) 0.50 
RCA & LCX 0% (0) 0.99% (1) 0.50 
Lesion Class    
 A 13.86% (14) 14.85% (15) 0.84 
 B1 20.79% (21) 22.77% (23) 0.73 
 B2 25.74% (26) 25.74% (26) 1.00 
 C 39.6% (40) 36.63% (37) 0.66 
% stenosis    
 >90% 49.5% (50) 52.47% (53) 0.67 
 80-90% 48.51% (49) 44.55% (45) 0.57 
 <80% 1.98% (2) 2.97% (3) 0.65 
Calcification    
None/Mild 72.27% (73) 70.29% (71) 0.76 
Moderate 19.8% (20) 19.8% (20) 1.00 
Severe 7.92% (8) 9.9% (10) 0.62 
Tortuosity    
<45 90.09% (91) 82.17% (83) 0.11 
45-90 9.9% (10) 17.82% (18) 0.11 
Thrombus 45.54% (46) 36.63% (37) 0.2 
Pre TIMI Flow    
0 41.58% (42) 52.47% (53) 0.12 
1 34.65% (35) 23.76% (24) 0.09 
2 18.81% (19) 14.85% (15) 0.45 
3 4.95% (5) 8.91% (9) 0.27 
 
 
Over all MACE rate reported for both of the groups was 0.99% Vs 0.99% (P=1) at one month, 
0.99% Vs 2.97% (P=0.34) at three months, 2.97% Vs 3.96% (P=0.7) at six months and 3.96% Vs 6.93% 
(P=0.36) at twelve months in Cohort-1 & Cohort-2 respectively (Figure 4).  
Safety and efficacy study result demonstrated that over all MACE and mortality rate appears lower 
in DES group compare to BMS group. However, it was not significant statistically. Further long term study is 
required to get more viable results with larger population.   
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Figure 4. Over all Major Adverse Cardiac Event w
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